First Eagle Investment Management LLC Sells 30,400 Shares of CareDx, Inc (NASDAQ:CDNA)

First Eagle Investment Management LLC trimmed its position in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 5.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 563,914 shares of the company's stock after selling 30,400 shares during the period. First Eagle Investment Management LLC owned approximately 1.05% of CareDx worth $12,073,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of CDNA. Principal Financial Group Inc. purchased a new stake in shares of CareDx during the 3rd quarter worth approximately $557,000. KBC Group NV purchased a new stake in CareDx during the 3rd quarter valued at $99,000. Royce & Associates LP raised its holdings in CareDx by 0.3% during the 3rd quarter. Royce & Associates LP now owns 393,286 shares of the company's stock valued at $12,280,000 after buying an additional 1,000 shares during the period. Quest Partners LLC raised its holdings in CareDx by 37.8% during the 3rd quarter. Quest Partners LLC now owns 5,611 shares of the company's stock valued at $175,000 after buying an additional 1,540 shares during the period. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in CareDx by 78.4% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 696,893 shares of the company's stock valued at $21,760,000 after buying an additional 306,222 shares during the period.

CareDx Stock Performance

CDNA stock traded up $0.46 during midday trading on Wednesday, reaching $19.17. The company's stock had a trading volume of 578,853 shares, compared to its average volume of 834,188. CareDx, Inc has a 1 year low of $7.42 and a 1 year high of $34.84. The stock has a fifty day simple moving average of $22.08 and a two-hundred day simple moving average of $24.14. The firm has a market capitalization of $1.06 billion, a price-to-earnings ratio of -7.10 and a beta of 1.95.

Remove Ads

CareDx (NASDAQ:CDNA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported $1.51 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The business had revenue of $86.58 million for the quarter, compared to the consensus estimate of $84.56 million. As a group, analysts forecast that CareDx, Inc will post -0.9 EPS for the current fiscal year.

Analysts Set New Price Targets

CDNA has been the topic of several recent research reports. Wells Fargo & Company upgraded CareDx from an "underweight" rating to an "equal weight" rating and decreased their price target for the company from $28.00 to $24.00 in a report on Wednesday, January 15th. StockNews.com upgraded CareDx from a "hold" rating to a "buy" rating in a report on Wednesday, February 26th. Stephens restated an "overweight" rating and set a $40.00 price target on shares of CareDx in a report on Thursday, February 27th. Finally, HC Wainwright reduced their target price on CareDx from $26.00 to $25.00 and set a "neutral" rating on the stock in a research note on Monday, March 3rd. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, CareDx presently has a consensus rating of "Moderate Buy" and an average price target of $31.83.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.